Generic Arcapta Availability

Last updated on Jun 11, 2025.

Arcapta is a brand name of indacaterol, approved by the FDA in the following formulation(s):

ARCAPTA NEOHALER (indacaterol maleate - powder;inhalation)

• Manufacturer: NOVARTIS
  Approval date: July 1, 2011
  Strength(s): EQ 75MCG BASE (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arcapta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Beta2-adrenoceptor agonists
  Patent 6,878,721
  Issued: April 12, 2005
  Inventor(s): Cuenoud; Bernard et al.
  Assignee(s): Novartis AG (Basel, CH)
  

  Compounds of formula ##STR1##
  in free or salt or solvate form, where Ar is a group of formula ##STR2##
  Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  Patent expiration dates:

  • February 25, 2025
    
    ✓ 
    Patent use: THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Inhaler device
  Patent 8,479,730
  Issued: July 9, 2013
  Inventor(s): Ziegler Dominik & Smetham Grant & Citterio Mauro
  Assignee(s): Novartis AG
  

  An inhaler device () for powdered medicaments. The device () has a body () that has a recess () for holding a capsule containing a powdered medicament to be inhaled, at least one air passage () that is tangentially disposed to the recess () , and a mouthpiece () that includes a coaxially disposed inhalation passage () that communicates with the recess () of the body (). The body () has a pair of opposed spring () biased push-buttons () that each include at least one piercing element () for piercing the capsule when loaded in the recess (). The medicament is released from the pierced capsule when air is drawn through the air passage(s) () into the recess () and swirled about therein. The mouthpiece () is pivotally attached to the edge of the body () so that it is pivotable between an open loading position and a closed dispensing position about an axis that is perpendicular to the longitudinal axis of the inhaler ().

  Patent expiration dates:

  • October 11, 2028
    
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer